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Abstract Mucopolysaccharidosis type VI (MPS VI) is a
severe lysosomal storage disorder without central nervous
system involvement caused by arylsulfatase B (ARSB) de-
ficiency. MPS VI is characterized by dysostosis multiplex,
corneal clouding, heart valve defects and urinary excretion
of glycosaminoglycans (GAGs). The current treatment for
MPS VI is enzyme replacement therapy (ERT) which has
limited efficacy on bone, joints and heart valve disease, as
well as high costs. A potential therapeutic approach for the
subgroup of MPS VI patients that carry nonsense mutations
is to enhance stop-codon read-through, using small mole-
cules, to restore production of the full-length ARSB protein.
In this study we investigated whether two compounds
known to induce stop codon read-through, the aminoglyco-
side gentamicin and PTC124, can promote read-through of
four different ARSB nonsense mutations (p.R315X,
p.R327X, p.Q456X and p.Q503X) associated with
MPS VI and enable the synthesis of full-length func-
tional ARSB protein in patients fibroblast cell lines. Our
study demonstrates that PTC124 but not gentamicin,
increases the level of ARSB activity in three MPS VI
patient fibroblast cell lines. In two of them the levels of
ARSB activity obtained were significantly higher than
in untreated cells, reaching ≤2.5 % of those detected in
wild-type fibroblasts and resulting in significant reduc-
tion of lysosomal size. Since even small increases in
enzyme activity can dramatically influence the clinical
phenotype of MPS VI, our study suggests that pharma-
cological read-through may be combined with ERT po-
tentially increasing therapeutic efficacy in those patients
bearing nonsense ARSB mutations.
Introduction
Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syn-
drome; OMIM #253200) is an autosomal recessive lyso-
somal storage disorder (LSD), that belongs to the group of
mucopolysaccharidoses (MPS). The MPS are caused by
defects in lysosomal enzymes that results in widespread
intra- and extra-cellular accumulation of glycosaminogly-
cans (GAGs). MPS VI is caused by deficiency of the en-
zyme arylsulfatase B [ARSB] (N-acetylgalactosamine-4-
sulfatase; EC 3.1.6.12) which removes the C4 sulfate ester
group from the N-acetylgalactosamine sugar residue at the
nonreducing terminus of the glycosaminoglycans dermatan
sulfate and chondroitin sulfate (Neufeld and Muenzer 2001).
Deficiency of ARSB results in the intralysosomal storage
and urinary excretion of these partially degraded GAGs. The
ARSB gene encodes for a polypeptide precursor of 533
amino acids, with a molecular weight of 55.8 kDa that is
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translocated into the lumen of the endoplasmic reticulum.
Subsequently the protein is glycosylated (66 kDa) and then
processed into a mature form (57 kDa) (Litjens et al 1989).
ARSB is secreted from normal cells, up taken by adjacent
cells and directed to the lysosomal compartment through
binding to the mannose-6 phosphate receptor (MPR) present
on the plasma and endosomal membranes of most cell types
(Dahms et al 1989). The enzyme reuptake by MPR that
results in cross-correction of ARSB-deficient cells repre-
sents the basis for the current treatment strategies: the bone
marrow/hematopoietic stem cell transplantation and the en-
zyme replacement therapy (ERT) (Valayannopoulos et al
2010). However, each of these treatments presents limita-
tions and therapies that efficiently correct the bone, heart
and central nervous system (CNS) anomalies of MPS are
currently unavailable.
Therefore, there is need for more effective therapeutic
strategies for MPS VI. Gene therapy, for instance, is aiming
at converting liver in a “factory” for sustained systemic release
of ARSB following a single intravascular administration of
therapeutic viral vectors (Cotugno et al 2011). However, the
safety and efficacy of this strategy has yet to be demonstrated
in humans. Another therapeutic option can be used inMPS VI
patients that bear premature stop-codon (PTC) mutations. The
approach aims at suppressing the effect of the PTC by induc-
ing its translational read-through (Manuvakhova et al 2000).
Indeed, it has recently been demonstrated that certain low-
molecular-weight drugs can influence the fidelity of stop
codon recognition and restore production of full-length pro-
teins (Linde and Kerem 2008). The two read-through inducer
drugs that are most widely used are the aminoglycoside gen-
tamicin and PTC124. Gentamicin antimicrobial effect is
exerted by binding to polysomes and interfering with protein
synthesis causing misreading and premature termination of
mRNA translation (Brunton et al 2006). Gentamicin-
enhanced stop codon read-through has been used as a thera-
peutic strategy for genetic diseases, including cystic fibrosis,
Duchenne muscular dystrophy and ataxia-teleangectasia
(Howard et al 2000; Du et al 2002; Lai et al 2004). Neverthe-
less, limitations on the use of gentamicin include its relatively
low cell permeability and its toxic side effects (e.g., kidney
damage and hearing loss). PTC therapeutics has recently
developed a new, more-efficient read-through inducing drug,
known as PTC124. PTC124 is an orally-bioavailable small
molecule compound that promotes dose-dependent suppres-
sion of premature translation termination without concomitant
effects on normal termination or mRNA decay. Various Phase
II and Phase II-III clinical trials to prove the safety of this
compound have been completed (http://clinicaltrials.gov/ct2/
results?term0ataluren). PTC-124 has high permeability and
unlike aminoglycosides, it has not been associated with seri-
ous toxic side effects (Hirawat et al 2007). PTC124 probably
acts at a ribosomal location different from the one used by
aminoglycosides since it is part of a structurally distinct class
of drugs (Hirawat et al 2007).
Approximately 33 % of inherited or acquired diseases are
due to PTCs (Mendell and Dietz 2001). PTCs have been
identified in a large cohort of patients with MPS (Brooks et
al 2006); in particular, ARSB mutational analysis in MPS
VI patients has allowed to identify 16 different ARSB
nonsense mutations (Human Gene Mutation Database;
http://www.hgmd.cf.ac.uk/ac/index.php, last access on
January 2012) which can be potential targets of stop codon
read-through. However, so far, the only evidence that
supports the efficacy of stop codon read-through for MPS
has been in cells from MPS I patients with PTC mutations.
Gentamicin treatment of these cells resulted in increase
iduronidase activity, up to 3 % of wild-type enzyme levels,
which reduced substrate storage (Keeling et al 2001).
In the current study we investigated whether gentamicin
and PTC124 have the potential to read-through ARSB PTCs
and increase enzyme activity in MPS VI patients cell lines.
Our results indicate that PTC124-mediated stop codon
read-through significantly increases ARSB activity
which results in reduction of GAG storage as demon-
strated by the significant decrease in lysosomal size
observed in drug-treated MPS VI cells.
Results
Reduction of baseline ARSB activity levels in MPS VI cell
lines for more sensitive measurement of PTC read-through
To test the feasibility of stop codon read-through for MPS
VI, we used four MPS VI primary fibroblast cell lines
(Table 1), cells from a normal individual and cells from an
MPS VI patient (ML5), without PTCs and thus not suscep-
tible to read-through, as control.
Stop codon read-through can result in subtle increments
in protein levels therefore it is essential to have a cellular
system in which pre-treatment gene product levels are con-
stant and predictable. During the initial stage of this study
we observed that this is not the case for ARSB enzymatic
activity in MPS VI primary fibroblast cell lines; we hypoth-
esised that this may be due to ARSB uptake from culture
medium, thus resulting in variable baseline ARSB activity
levels. For example, MPS VI cells that bear mutations
causing a severe phenotype and for which the expected
ARSB levels should be below the detection limit of the
enzymatic assay, routinely exhibited ARSB activity levels
ranging between 1.5 % and 6 % of wild-type ARSB activity.
To test if there is uptake from the medium and to reduce
the baseline ARSB activities, MPS VI primary fibroblasts
were maintained in culture medium with either 2.5 mM or
5 mM mannose-6-phosphate (M6P), in order to saturate
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MPRs and to inhibit exogenous ARSB uptake from the
medium (Supplementary Fig. 1a). The levels of endogenous
ARSB activity from MPS VI cells treated with M6P were
lower than those from untreated cells and were almost
undetectable in the presence of 5 mMM6P. Thus, all experi-
ments have been performed in the presence of 5 mM M6P.
MPRs are required for the normal production of lysosomal
enzymes, as well as their proper maturation and intracellular
delivery to lysosomes (Dahms et al 1989), thus we assessed
if culturing primary fibroblasts in the presence of M6P
interferes with lysosomal enzymes processing. We tested
the activity of two additional lysosomal enzymes in MPS
VI cells cultured or not in the presence of M6P. We did not
observe any significant differences in the activity of β-
galactosidase and α-1-4-glucosidase between cells treated
or not with M6P (Supplementary Fig. 1b), suggesting that
M6P addition does not interfere with normal intracellular
lysosomal enzymes processing.
Assessment of ARSB mRNA levels in MPS VI cell lines
before addition of read-through inducing compounds
Because transcripts carrying PTCs represent the template for
read-through treatment, it was hypothesized that nonsense-
mediated mRNA decay (NMD) might impair the read-
through response (Kuzmiak and Maquat 2006). Conse-
quently, analyzing the levels of mRNA before setting up a
read-through treatment may be instrumental to identify
patients with highest potential to respond to the treatment.
The NMD pathway is known to cause the degradation of
mRNAs that carry a PTC in a position 50 nucleotides
upstream of the last exon–exon junction (Nagy and Maquat
1998). However, because there are exceptions to this rule
(Linde and Kerem 2008) and exceptions are not usually
predictable, it is advisable to confirm experimentally if a
PTC-bearing mRNA is an NMD target.
Our analysis included mutant transcripts predicted to
escape NMD (ML3 and ML4) as well as two ARSB tran-
scripts (ML1 and ML2) expected to be subject to NMD
based on previous reports (Fig. 1a) (Garrido et al 2008).
Our RT-PCR results shown in Fig. 1b confirm that NMD
of the mutant ARSB transcripts can be both PTC-position
dependent and independent. Indeed, we found high (ML4
cell line) and low (ML1 and ML2 cell lines) ARSB mRNA
levels, as one would predict from the position of the
corresponding PTC (Fig. 1a). In the ML3 cell line, where
the PTC position is not predicted to trigger NMD, we
observed transcript levels lower than expected (please note
that the band in the ML3 lane in Fig. 1b results from two
consecutive cycles of PCR amplification) suggesting that
susceptibility of the transcripts to NMD predicted on the
basis of the PTC position should be regarded only as an
indication and should be verified in experimental condi-
tions. In conclusion, we found that before addition of read-
through inducing compounds all MPS VI cell lines are
potentially responsive to treatment, as we found in all of
them detectable levels of ARSB transcript spared by the
NMD process. However, the presence of ARSB transcript
is necessary but not sufficient for drug-induced read-through
to occur since factors like: i) the stop codon context
sequence; ii) the sensitivity of the detection system and
iii) the cell culture conditions can dramatically influence
the read-though efficiency.
As treatment with neither gentamicin nor PTC124 has
been reported to affect mRNA levels (Welch et al 2007; Du
et al 2008), we did not perform ARSB transcript level
analysis following incubation with the drugs.
Treatment with PTC124 but not with gentamicin significantly
increases ARSB enzymatic activity and results in GAG
clearance in MPS VI cell lines
To test the efficacy of read-through induction, we selected two
known read-through inducing compounds, gentamicin (1 mg/
ml) and PTC124 (3.3 μM and 10 μM), and one incubation
time point (48 h). The drug doses were selected based on
previously published data (Keeling et al 2001; Welch et al
2007). As time points we tested 24, 48 and 72 h after drug
administration and found that the highest increase in enzymatic
activity is observed at 48 h (data not shown).
Table 1 MPS VI patient fibroblasts cell lines
Patient ID Nonsense mutation
Amino acid substitution Nucleotide substitution Stop codon context Exon Second mutation Phenotype
ML1 R315X c.943 C>T cuuUGAgga V Del exon V Severe
ML2 R327X c.979 C>T gucUGAggg V R327X Severe
ML3 Q456X c.1366 C>T ucuUAAuac VIII C447S Severe
ML4 Q503X c.1507 C>T cuaUAGuuc VIII Q503X Intermediate
Mutation Second Mutation Comments
ML5 c.1213+6 T>C c.1213+6 T>C Alternative splicing Intermediate
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As shown in Fig. 2a, although the ARSB background
activity has not been completely abolished by the incubation
with M6P, and some variability is still observed among the
different cell lines, no recovery of ARSB activity was ob-
served following incubation with gentamicin in the four
MPS VI cell lines used. Notably, we were not able to
perform experiments on early culture passages for any of
the MPS VI cell lines and this may have been critical when
using gentamicin. Indeed, recent studies have reported that
membrane permeability to aminoglycosides varies signifi-
cantly between different cell types and culture passages;
particularly, the permeability or efflux of gentamicin in
cultured primary fibroblasts is reduced with increasing the
cell passage number (Schroeder et al 1984; Keeling et al
2001), suggesting that the primary fibroblast cell line pas-
sage is crucial for gentamicin activity. Thus it is possible
that the culture passage at which our MPS VI cell lines were
tested for gentamicin-induced suppression of PTCs was not
optimal to detect its effect. Besides, to overcome the re-
duced membrane permeability we used the highest genta-
micin concentration which has been reported in the literature
(Manuvakhova et al 2000). However, gentamicin treatment
at this concentration appears to be toxic since all cell
lines, except those derived from patient ML2, present
lower ARSB activity in the presence than in the absence
of gentamicin (Fig. 2a).
After PTC124 treatment, increased ARSB activity was
detected in all but one MPS VI patient fibroblast cell lines
(Fig. 2b). In particular, we found that PTC124 treatment
significantly increased ARSB activity of ML2 fibroblasts: to
2.32 nmol/mg of protein/h (PTC124 [10 μM]) and
1.31 nmol/mg of protein/h (PTC124 [3.3 μM]), thrice and
twice the levels of untreated cells (0.74 nmol/mg of protein/
h), respectively. In ML1 and ML3 fibroblasts the increase in
ARSB activity was detected only with the highest PTC124
concentration (10 μM) and, even if in both cell lines the
ARSB activity almost doubled in treated compared to un-
treated control cells, the increase was significant only in
ML1 cells (Supplementary Table 1). Finally, treatment with
PTC124 was ineffective in both the ML4 line and, as
expected, in the control ML5 cell line. Notably, ML1 and
ML2 cell lines carry PTCs with the highest read-through
potential (Manuvakhova et al 2000), which inversely corre-
lates with the translation-termination efficiency, i.e., UGA
has the highest read-through efficiency, followed by UAG
and, to a lesser extent, UAA (Manuvakhova et al 2000;
Howard et al 2000).
Since PTC-read-through induces the insertion of random
aminoacidic residues at the stop codon position, some of the
resulting full-length proteins will be wild-type and retain
catalytic activity while some will contain aminoacidic sub-
stitutions which might impair catalytic activity. Since the
latter will not be detected by the ARSB enzymatic assay, we
analyzed the same cellular extracts used for the ARSB
enzymatic assay by Western blot analysis with anti-ARSB
antibodies (data not shown). Western blot analysis should
Fig. 1 a Schematic representation of the ARSB PTC mutations pres-
ent in the MPS VI cell lines. EJC: exon-junction complex. (ML1),
(ML2), (ML3) and (ML4): MPS VI cell lines with corresponding
PTCs. b ARSB mRNA levels in MPS VI cell lines. RT-PCR reactions
were performed on total RNA to amplify: i) a 632 bp ARSB cDNA
fragment (from exon 7 to the 3′-UTR) from ML1, ML2, ML4 and
wild-type (non-MPS VI individuals); ii) a 377 bp cDNA fragment
(from exon 8 to the 3′-UTR) from ML3; iii) a 839 bp β-Actin frag-
ment, as control. The resulting PCR products were separated on a 1 %
agarose gel. Lanes marked with (asterisk) correspond to two consecu-
tive PCR rounds of amplifications performed on the same template
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allow semi-quantitative measurements of ARSB protein
independently of its enzymatic activity. We were not able
to detect any increase in the levels of ARSB protein in cells
treated with PTC124 compared to untreated cells (data not
shown). However, given the low-resolution of the Western
blot, we cannot exclude that this might have hampered the
detection of low levels of ARSB protein produced in
PTC124-treated MPS VI cells.
To further explore if the ARSB activity levels achieved
after PTC124 treatment can reverse abnormal GAG storage,
we performed electron microscopy (EM) analysis of both
the MPS VI cell line 2 (ML2), the best responder to
PTC124, and wild-type fibroblasts as control (Fig. 3a, b).
ML2 cells were incubated at the highest PTC124 concen-
tration (10 μM) for 2 and 10 days. As shown in Fig. 3
(panels c, d), fibroblasts from ML2 patient exhibit numerous
large lysosome-like structures whose size is significantly
reduced after PTC124 treatment (panels e, f, g); this trend
to normalization observed after 2 days of incubation with
PTC124 is retained after 10 days of treatment (data not
shown). These data support the efficacy of PTC124 at
reducing lysosomal storage and engulfment, one of the main
features of MPS VI.
Discussion
A nonsense mutation prematurely halts the synthesis of a
protein: stop codon read-through is being considered as a
potential therapeutic strategy (either alone or in combination
with other therapies) for recessive genetic diseases due to
nonsense mutations. Indeed several studies, most of which
performed in vitro, have shown its efficacy (Linde and
Kerem 2008).
Fig. 2 a Gentamicin does not induce significant PTCs read-through in
MPS VI fibroblasts. ML1 (passage 6), ML2 (passage 10), ML3 (pas-
sage 9), ML4 (passage 14) and ML5 (passage 8) fibroblasts were
cultured in the presence of 5 mM M6P for 7–13 days and then
incubated or not for 48 h with 1 mg/ml gentamicin. Data are shown
as average + standard error (SE) (two independent experiments). b
PTC124-mediated stop codon read-through in MPS VI fibroblasts.
ML1 (passage 6), ML2 (passage 10), ML3 (passage 9), ML4 (passage
14) and ML5 (passage 8) fibroblasts were cultured in the presence of
5 mM M6P for 7–13 days and then incubated or not for 48 h with
3.3 μM PTC124, 10 μM PTC124 or 1.6 % DMSO (mock treated).
Data are shown as average + SE of two independent experiments for
ML3, ML4 and ML5 cells; data from ML1 and ML2 cells are from
three independent experiments. * P≤0.05 indicates the statistical dif-
ference between PTC124- and DMSO-treated cells. Additional t-test
values information are found in Supplementary Table 1
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For this purpose, the two drugs that are most widely used
and most promising are the aminoglycoside gentamicin and
the investigational new drug PTC124 (Welch et al 2007).
Indeed, both are able to induce a beneficial stop codon read-
through based on their ability to alter the ribosomal proof-
reading activity on premature termination codons, while
remaining ineffective on bona fide termination codons
(Rospert et al 2005). There are ongoing clinical studies
Fig. 3 Treatment with PTC124
reduces the size of lysosome-
like organelles in ML2 fibro-
blasts. Wild-type (control, WT)
and ML2 fibroblasts were cul-
tured in the presence of 5 mM
M6P for 10 days and then ML2
cells were incubated with
10 μM PTC124 or 1.6 %
DMSO (mock treated) for 48 h,
then fixed and prepared for EM
as described in Materials and
Methods. Asterisks in each
image indicate the center of
lysosome-like organelles. Pan-
els a and b show representative
lysosomes in wild-type fibro-
blasts. ML2 fibroblasts exhibit
numerous large lysosome-like
structures (c, d). The same cells
treated with PTC124 show
lysosome-like structures of
reduced size (e, f). Graph in g
represents quantification of
lysosome size (100 structures of
lysosomal origin were analyzed
for each condition). The data is
expressed as the mean ± SD,
while *** P<0.001 indicates
the statistical difference be-
tween PTC124- and DMSO-
treated ML2 cells. Scale bar,
500 nm (nm: nanometers)
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testing the safety and efficacy of both, however, PTC124
may be preferable as its use is not associated with the
toxicity observed with prolonged administrations of amino-
glycosides. Notably, our study is one of the first which tests
the effect of PTC124 in LSD (Sarkar et al 2011), as only in
one additional report it has been shown that aminoglyco-
sides can suppress nonsense mutations within the iduroni-
dase gene mutated in MPS I (Keeling et al 2001; Wang et al
2012). A critical issue when considering this therapeutic
strategy is to establish whether the efficacy of the stop
codon read-through may be clinically relevant. LSDs, in-
cluding MPS VI, offer a unique opportunity to address this
as there is a well-defined correlation between residual enzy-
matic activity and disease severity: 5–10 % of enzymatic
activity is thus considered therapeutic in several LSDs
(Neufeld and Muenzer 2001). In addition, since the chemical
drugs that are used to influence stop codon read-through tend
to be lower in molecular weight and more diffusible than the
proteins used for ERT, it is possible that read-through drugs
will be able to reach sites of disease like bone, cartilage or
brain that are resistant to the conventional ERT. Since PTCs
are generally associated with low residual enzymatic activity
and severe clinical manifestations, a therapy that combines
both ERT and stop codon read-through may result in maxi-
mum substrate clearance and a more effective therapy for
MPS VI patients with severe symptoms (Brooks et al 2006).
Importantly, we set out to determine the potential of
pharmacological read-through on intact cells by analyzing
the effects of gentamicin and PTC124 on endogenous
nonsense-bearing transcripts directly, assuming that the
read-through effect could be quantified as an increase in
ARSB enzymatic activity compared to that detected in con-
trol untreated cells. Although we were able to detect signif-
icant increases in ARSB activity in MPS VI cells treated
with PTC124, the levels reached did not exceed 3 % of wild-
type. One possibility to explain these low levels, which
however are similar to those achieved by others in MPS I
cell lines, is that measuring ARSB activity may not be
sensitive enough to detect low increases, since cultured
MPS VI fibroblasts can uptake exogenous ARSB from the
culture medium and this might result in variable degrees of
baseline ARSB activity measured in control untreated fibro-
blasts. This might partially mask read-through-induced
increases in ARSB activity after treatment with read-
through agents, especially if this induction occurs at low
levels. Also, we cannot exclude that culturing cells with
M6P to block the uptake of exogenous ARSB, despite not
impacting the activity levels of two lysosomal enzymes
different from ARSB, might alter intracellular pathways
involved in lysosomal enzyme processing, possibly having
an effect on read-through efficacy.
Importantly, we show that PTC124-induced increase of
ARSB activity levels to 2.5 % of normal significantly
reduces lysosomal size suggesting that PTC124 induces
clearance of lysosomal storage. This further supports the
concept that slight increases in enzymatic activity can have
a profound impact on LSDs.
Altogether, our results suggest that PTC124-mediated
stop codon read-through has the potential to attenuate both
the biochemical and the morphological abnormalities of
MPS VI. Thus, PTC124 use could be considered in combi-
nation with ERT to enhance therapeutic efficacy in those
districts like bone or cartilage which could be reached more




Fibroblasts from MPS VI patients ML2, ML4 and ML5
were provided by the Telethon Cell line and DNA Bank
from Patients with Genetic Diseases (Dr Mirella Filocamo,
Gaslini Hospital Genoa, Italy). Fibroblasts from MPS VI
patient ML3 were provided by the Children Hospital,
University of Mainz, Germany. ML1 MPS VI and normal
control fibroblasts were available at the Department of
Pediatrics, Federico II University, Naples, Italy.
All cell lines were grown at 37 °C with 5%CO2, in
Dulbecco’s modified Eagle’s medium (DMEM, Celbio,
Milan, Italy) supplemented with 20 % fetal bovine serum
(FBS, Gibco, Invitrogen corporation, Carlsbad, CA, USA),
100U/ml penicillin and 100 μg/ml streptomycin (Sigma-
Aldrich, Milan, Italy). All experiments were conducted on
fibroblasts at 50–70 % confluence and at various passages
(specified in the Results section). We performed three inde-
pendent replicates of those experiments in which drug treat-
ment resulted in increased enzymatic activity (PTC124
treatment of ML1 and ML2 cell lines), and duplicates of
those without significant enzymatic increase following
addition of read-through inducing compounds.
Reverse transcriptase-PCR
Fibroblasts were grown until confluence. Cells were washed
twice with Phosphate Buffer Saline (PBS, Gibco, Invitrogen
Corporation, Carlsbad, CA, USA) and harvested using tryp-
sin/EDTA (Gibco, Invitrogen Corporation, Carlsbad, CA,
USA) for 3–5 min; then the cell suspension was centrifuged
at 1200 g for 5 min. The cell pellet was then washed with
PBS and separated by centrifugation. The cell pellet was
used to isolate total RNA using the QIAshredder and the
RNeasy Minikit (Qiagen, Hilden, Germany). RNA was
quantified with a Nanodrop apparatus and analyzed on an
agarose gel.
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A reverse transcription reaction was carried out from
1 μg of total RNA using the SuperScript® III Reverse
Transcriptase (RT) (Invitrogen corporation, Carlsbad, CA,
USA), following the manufacturer’s recommendations. To
amplify an ARSB cDNA fragment, RT-PCR was carried out
using the following primers: forward 5′- CAT GGC TCC
AGC AAA GGA T – 3′ and reverse 5′ – GTC CCA AGG
CTTAGG AAA G – 3′ (product length of 632 bp). For ML3
fibroblasts, forward 5′-GGT TCC CTC CAC CGT CTT – 3′
and reverse 5′-GCCTGAGGTCCAACTTCC-3′ primers
were used to amplify an ARSB cDNA fragment (375 bp)
specific for the PTC-bearing allele.
β-actin was also amplified using the following primers:
forward 5′ – GTC CCA AGG CTT AGG AAA G – 3′ and
reverse 5′ – GTC CCA AGG CTT AGG AAA G – 3′
(product length of 839 bp).
PCRs were performed using TaQ Gold DNA polymerase
(Roche, Indianapolis, IN, USA) and consisted of 1 μl of
template cDNA, 1.25 U TaQ Gold DNA polymerase,
2.5 mM MgCl2 in the recommended buffer, 200 μM of
dNTPs, and 0.5 μM of each primer in a final volume of
25 μl. The reactions cycles used are the following: 5 min at
95 °C; 40 cycles of denaturation at 94 °C for 45 s, annealing
at 56 °C for 45 s and elongation at 72 °C for 85 s; final
extension step at 72 °C for 7 min. The amplification reac-
tions were performed in a T3000 Thermocycler (Biometra,
Goettingen, Germany). The resulting PCR products were
separated on a 1 % agarose gel. Samples from patients
ML1 and ML3 required two consecutive rounds of PCR
amplifications performed on the same template.
Gentamicin and PTC124 treatment
All the MPS VI cell lines were maintained in culture medium
containing 5 mM M6P, for a period of 7–13 days before and
during the incubation with the drugs.
Read-through induction cells were incubated in the pres-
ence of 1 mg/ml gentamicin (Sigma-Aldrich, Milan, Italy)
for 12, 24, 48 or 72 h. Stock solutions (6 mM) of PTC124
(Selleck Chemical LLC, Houston, USA) were prepared in
100 % DMSO (Sigma-Aldrich, Milan, Italy). Fibroblasts
were incubated in the presence of 3.3 μM, 10 μM PTC-
124 or 1.6 % DMSO (mock treated) for 48 h. During the
incubation time, cells were cultivated in the absence of
antibiotic drugs.
Protein extraction and ARSB activity assay
After the selected time point, cells were washed twice with
PBS and harvested using trypsin/EDTA for 3–5 min; then
the cell suspension was centrifuged at 1200 g for 5 min. The
cell pellet was then washed twice with PBS and then re-
centrifuged. The resulting supernatant was removed and
cells were lysed in water in the presence of a protease
inhibitor cocktail (Roche, Indianapolis, USA) with three
repeated cycles of freezing and thawing; cell debris were
eliminated by centrifugation at 13,000 rpm for 20 min; the
supernatant was collected and subjected to further analysis.
Total protein concentration in cellular extracts was mea-
sured using the colorimetric BCA protein assay kit (Pierce
Chemical Co, Boston, MA, USA) and a standard curve with
seven different concentrations of bovine serum albumine
(Pierce Chemical Co, Boston, MA, USA): 0.05, 0.1, 0.2,
0.4, 0.6, 0.8 and 1 μg/μl. Colorimetric reaction was
quantified with an absorbance reader (Infinite F200,
Tecan, Mannedorf, Switzerland) using a 560 nm filter.
The ARSB activity assay was performed as described
previously (Tessitore et al 2008). Briefly, 15 ug of proteins
were incubated with 40 μl of the fluorogenic substrate, 4-
methylumbelliferyl-sulfate potassium salt (12.5 mM Sigma-
Aldrich, Milan, Italy), for 3 h at 37 °C in the presence of 40 μl
of silver nitrate (0.75 mM, Carlo Erba, Milan, Italy), which is
known to inhibit the activity deriving from other sulfatases.
The reaction was stopped by adding 200 μl of the carbonate
stop buffer (0.5 M NaHCO3/0.5 M Na2CO3, pH 10.7), and
the fluorescence of the 4-methylumbelliferone liberated was
measured in a fluorimeter (Infinite F200, Tecan, Mannedorf,
Switzerland) using 365 nm excitation and 460 nm emission.
The enzyme activities were calculated using a standard curve
of the fluorogenic product, 4-methylumbelliferone (Sigma-
Aldrich, Milan, Italy). β-galactosidase and α-glucosidase ac-
tivities were assayed as previously described, using the appro-
priate substrates. β-galactosidase (4-methylumbelliferyl-b-D-
galactoside, Sigma-Aldrich, Milan, Italy) and α-glucosidase
(4-methylumbelliferyl-b-D-glucoside, Sigma-Aldrich, Milan,
Italy) (Kresse et al 1982). For cellular extracts the activity is
expressed as nmol/mg protein/h.
Electron microscopy (EM) analysis of MPS VI fibroblasts
Fibroblasts from the ML2 MPS VI patient were treated for
2 days with either PTC124 10 μM or 1.6 % DMSO (mock
treated). Wild-type fibroblasts were used as controls. Cells
were fixed in 1 % glutaraldehyde in 0.2 M HEPES buffer,
post-fixed in uranyl acetate and in OsO4. After dehydration
through a graded series of ethanol, the cells were embedded
in Epoxy resin (Epon 812, Sigma-Aldrich, St. Louis, MO,
USA) and polymerized at 60 °C for 72 h. From each sample,
thin sections were cut with a Leica EM UC6 ultramicrotome
(Leica Mycosystems, Vienna, Austria). EM images were
acquired from thin sections using an FEI Tecnai-12 electron
microscope (FEI, Eindhoven, Netherlands) equipped with
an ULTRA VIEW CCD digital camera (Soft Imaging
Systems GmbH, Munster, Germany). Quantification of
lysosome-like organelles size was performed using the iTEM
software (Soft Imaging Systems GmbH, Munster, Germany).
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Statistical analysis
The statistical analysis of data obtained from each experi-
mental group was performed by using the unpaired two-tail
Student’s t-test. A P value ≤0.05 was considered significant.
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